18 results
6-K
EX-99.1
GLPG
Galapagos NV
25 Mar 21
Galapagos appoints Bart Filius as President and Chief Operating Officer
6:00am
, CEO Onno van de Stolpe will maintain oversight of the research and development activities, while Bart Filius will take responsibility for business
6-K
EX-99.3
GLPG
Galapagos NV
11 May 21
Current report (foreign)
2:10pm
Completion Date pursuant to Section 6.3.
“Promotional Review” means the review and oversight of the compliance with Applicable Law and Applicable Guidelines … shall have no oversight or decision-making authority with respect to any activities conducted under this Agreement other than (A) […***…], which
6-K
EX-99.1
GLPG
Galapagos NV
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
collection and CAR-T infusion), and greater physicians oversight throughout the process.
About Relapsed/refractory multiple myeloma (rrMM)
Multiple myeloma
6-K
EX-99.3
GLPG
Galapagos NV
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
Amendment provided that, on and after the Amendment Effective Date, subject to the oversight of the Committees established thereunder and those … committee (the “JSC”) which will monitor and provide strategic oversight of the activities under this Agreement and facilitate communications between
6-K
EX-99.1
GLPG
Galapagos NV
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
and CAR-T infusion), and greater physicians oversight throughout the process.
About the EUPLAGIA-1 study (EudraCT 2021-003815-25)EUPLAGIA-1 is an ongoing
6-K
EX-99.2
vcjagt2w
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
DRS
1rk4t78b 88h6atruq
6 Feb 15
Draft registration statement
12:00am
6-K
EX-99.2
evfa7m8 v3dbtgwyn
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
20-F
ohhybiwu
25 Mar 16
Annual report (foreign)
12:00am
DRS/A
EX-10
eg1iekeflv73p2
4 Mar 15
Draft registration statement (amended)
12:00am
DRS/A
EX-10
erfq91 pfr9ehw5r
4 Mar 15
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next